An "off-the-shelf" fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies.

An "off-the-shelf" fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies.
复制标题

DOI:
10.1038/s41375-018-0065-5
复制
发表时间:
2018-09
期刊:
影响因子:
11.4
通讯作者:
DiPersio JF
DiPersio JF
中科院分区:
医学1区
文献类型:
--
作者:
Cooper ML;Choi J;Staser K;Ritchey JK;Devenport JM;Eckardt K;Rettig MP;Wang B;Eissenberg LG;Ghobadi A;Gehrs LN;Prior JL;Achilefu S;Miller CA;Fronick CC;O'Neal J;Gao F;Weinstock DM;Gutierrez A;Fulton RS;DiPersio JF

文献摘要

参考文献

被引文献

相似文献

T细胞恶性肿瘤代表了一组血液学癌症,在没有有效靶向治疗的患者中具有高复发率和死亡率。嵌合抗原受体(CAR)T细胞和恶性T细胞之间靶抗原的共享表达限制了CAR-T的发展,因为非预期的CAR-T自相残杀和无法收获足够的自体T细胞。在这里,我们描述了一种抗手足相残的“现成”CAR-T(或UCART 7),它靶向CD 7 + T细胞恶性肿瘤,并且通过CRISPR/Cas9基因编辑,缺乏CD 7和T细胞受体α链(TRAC)表达。UCART 7在体外和体内表现出针对人T细胞急性淋巴细胞白血病(T-ALL)细胞系和原代T-ALL的功效,而不会诱导异种GvHD。抗杀兄弟药、同种异体耐受的“现成”CAR-T代表了治疗复发性和难治性T-ALL和非霍奇金T细胞淋巴瘤的策略,而不需要自体T细胞。
T cell malignancies represent a group of hematologic cancers with high rates of relapse and mortality in patients for whom no effective targeted therapies exist. The shared expression of target antigens between chimeric antigen receptor (CAR) T cells and malignant T cells has limited the development of CAR-T because of unintended CAR-T fratricide and an inability to harvest sufficient autologous T cells. Here we describe a fratricide resistant ‘off-the-shelf’ CAR-T (or UCART7) that targets CD7+ T cell malignancies and, through CRISPR/Cas9 gene editing, lacks both CD7 and T cell receptor alpha chain (TRAC) expression. UCART7 demonstrates efficacy against human T cell acute lymphoblastic leukemia (T-ALL) cell lines and primary T-ALL in vitro and in vivo without the induction of xenogeneic GvHD. Fratricide resistant, allo-tolerant ‘off-the-shelf’ CAR-T represents a strategy for treatment of relapsed and refractory T-ALL and non-Hodgkin’s T cell lymphoma without a requirement for autologous T cells.
DOI: 10.1038/nbt.3290
发表时间: 2015-09
影响因子: 46.9
作者:
Hendel A;Bak RO;Clark JT;Kennedy AB;Ryan DE;Roy S;Steinfeld I;Lunstad BD;Kaiser RJ;Wilkens AB;Bacchetta R;Tsalenko A;Dellinger D;Bruhn L;Porteus MH
通讯作者: Porteus MH
DOI: 10.1038/nature21405
发表时间: 2017-03-02
期刊: Nature
影响因子: 64.8
作者:
Eyquem J;Mansilla-Soto J;Giavridis T;van der Stegen SJ;Hamieh M;Cunanan KM;Odak A;Gönen M;Sadelain M
通讯作者: Sadelain M
DOI: 10.1128/jvi.72.11.8463-8471.1998
发表时间: 1998-11-01
影响因子: 5.4
作者:
Dull, T;Zufferey, R;Naldini, L
通讯作者: Naldini, L
DOI: 10.1182/blood-2015-02-629527
发表时间: 2015-08-20
期刊: BLOOD
影响因子: 20.3
作者:
Mamonkin, Maksim;Rouce, Rayne H.;Brenner, Malcolm K.
通讯作者: Brenner, Malcolm K.
DOI: 10.1200/jco.2003.10.116
发表时间: 2003-10-01
影响因子: 45.3
作者:
Goldberg, JM;Silverman, LB;Asselin, BL
通讯作者: Asselin, BL